<DOC>
	<DOCNO>NCT02949193</DOCNO>
	<brief_summary>This randomize , double-blind , active-controlled , phase III clinical trial investigate efficacy safety evogliptin add ongoing metformin monotherapy patient type 2 diabetes inadequate glycemic control</brief_summary>
	<brief_title>Efficacy Safety Evogliptin add-on Metformin Patients With type2 Diabetes</brief_title>
	<detailed_description>1 . Evogliptin 5mg Group : Administration Evogliptin 5mg add-on metformin 0-52 week . 2 . Sitagliptin 100mg Group : Administration Sitagliptin 100mg add-on metformin 0-24 week , Evogliptin 5mg add-on metformin 24-52 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Subjects 6.5 % ≤HbA1c≤11.0 % screen Subjects treat 1,000mg/day high dose metformin least 6 week prior screen among people treat metformin monotherapy least 12 week screen Subjects 20kg/m2≤BMI≤40kg/m2 screen Subjects fast plasma glucose≥270mg/dL screen Patients type 1 diabetes mellitus , secondary diabetes mellitus gestational diabetes mellitus Subjects history myocardial infarction , cerebral infarction within 6 month prior screen Subjects ALT AST 2.5 time high upper normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>